We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+21.05%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$340M
AUM Growth
-$154M
Cap. Flow
-$164M
Cap. Flow %
-48.19%
Top 10 Hldgs %
53.86%
Holding
71
New
18
Increased
9
Reduced
13
Closed
25

Top Buys

1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20.8M
2
BLUE
bluebird bio
BLUE
+$18.5M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.97M

Top Sells

1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$20.2M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$17.5M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.7M
4
VTRS icon
Viatris
VTRS
+$14.4M
5
IMMU
Immunomedics Inc
IMMU
+$12.1M

Sector Composition

1 Healthcare 84.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FXF icon
51
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
– –
-45,800
Closed -$4.51M
INCY icon
52
PUT
Incyte
INCY
$23.4B
– –
-8,333
Closed -$83.3M
KPTI icon
53
Karyopharm Therapeutics
KPTI
$216M
– –
-5,119
Closed -$1.03M
NGNE icon
54
Neurogene
NGNE
$744M
– –
-20,000
Closed -$5.63M
SAGE
55
DELISTED
Sage Therapeutics
SAGE
– –
-11,100
Closed -$1.79M
SLDB icon
56
Solid Biosciences
SLDB
$858M
– –
-25,667
Closed -$2.89M
TVTX icon
57
Travere Therapeutics
TVTX
$5.27B
– –
-314,367
Closed -$7.03M
VTRS icon
58
Viatris
VTRS
$20.1B
– –
-350,000
Closed -$14.4M
GTHX
59
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-150,000
Closed -$5.56M
IMGN
60
DELISTED
Immunogen Inc
IMGN
– –
-7,500
Closed -$225K
INFI
61
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-1,750,000
Closed -$3.67M
KDNY
62
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-100,000
Closed -$4.65M
JNCE
63
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-125,092
Closed -$2.8M
CNCE
64
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-350,000
Closed -$8.02M
CLVS
65
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-75,000
Closed -$3.96M
NBRV
66
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-800
Closed -$1.01M
MNTA
67
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-500,000
Closed -$9.07M
AGN
68
DELISTED
Allergan plc
AGN
– –
-45,000
Closed -$7.57M
TSRO
69
DELISTED
TESARO, Inc.
TSRO
– –
-61,900
Closed -$3.54M
AVXS
70
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-135,000
Closed -$16.7M
BHVN
71
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-550,000
Closed -$17.5M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Ghost Tree Capital held 71 positions worth $340M, down 31% from $494M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ghost Tree Capital withdrew a net $164M in Q2 2018, closing 25 positions and reducing 13 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 63% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Alnylam Pharmaceuticals worth $20.7M.

  • Ghost Tree Capital's largest Q2 2018 buy was Alnylam Pharmaceuticals: 210,000 shares worth $20.7M.
  • Ghost Tree Capital added most to PTC Therapeutics in Q2 2018, an estimated $14.8M increase.
  • Ghost Tree Capital's biggest Q2 2018 reduction was Endocyte, Inc. Common Stock, cutting an estimated $20.2M.
  • Ghost Tree Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018, selling an estimated $17.5M.
  • Ghost Tree Capital's ten largest holdings make up 54% of its $340M portfolio in Q2 2018.
  • Ghost Tree Capital opened 18 new positions and closed 25 in Q2 2018.
  • Ghost Tree Capital's portfolio value fell 31% quarter-over-quarter to $340M.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.